Capital Flow Monitor · Sponsors · CIK 2141184
Ollin Biosciences, Inc.
1250 S. CAPITAL OF TEXAS HWY, AUSTIN, TX, 78746 · 512-885-4957
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$330.0M
Sold
$156.2M
% sold
47.3%
Investors
32
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | D ·current | 506(b) | $330.0M | $156.2M | 47.3% | 32 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Jason Ehrlich — Executive Officer / Director, AUSTIN, TX
2 other raises
- Build Capital Qualified Fund LP $6.0M of $25.0M · 24.0%
- Fruition Capital Fund II, LLC $14.1M of $14.1M · 100.0%
-
Paul Berns — Director, AUSTIN, TX
1 other raise
- ARCH Venture Fund XIV, L.P. $0 of $3.0B · 0.0%
-
Jason Coloma — Director, AUSTIN, TX
1 other raise
- Alloy Therapeutics, Inc. $30.0M of $40.0M · 75.1%
-
Cariad Chester — Director, AUSTIN, TX
1 other raise
- Plexium, Inc. $60.1M of $60.1M · 100.0%
- Fred Cohen — Director, AUSTIN, TX
-
Alaa Halawa — Director, AUSTIN, TX
3 other raises
- MC Healthcare Ventures II LP $0 of —
- Alloy Therapeutics, Inc. $30.0M of $40.0M · 75.1%
- InnovAccer Inc. $2.1M of —
- Travis Murdoch — Director, AUSTIN, TX
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.